1. JAK/STAT Signaling PI3K/Akt/mTOR MAPK/ERK Pathway
  2. Erythropoietin Receptor (EpoR)
  3. ASP7967 hemifumarate

ASP7967 hemifumarate is an orally active ligand of the RNA aptamer AC17-4 with a Kd of 12 nM. ASP7967 hemifumarate binds AC17-4 to regulate aptazyme-based and exon-skipping riboswitches, thereby enabling small-molecule-controlled transgene expression without exogenous protein factors. ASP7967 hemifumarate can be used for the study of synthetic RNA switches, gene expression regulation and AAV-based gene therapy-related expression control.

For research use only. We do not sell to patients.

ASP7967 hemifumarate

ASP7967 hemifumarate Chemical Structure

CAS No. : 1246958-42-8

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

ASP7967 hemifumarate is an orally active ligand of the RNA aptamer AC17-4 with a Kd of 12 nM. ASP7967 hemifumarate binds AC17-4 to regulate aptazyme-based and exon-skipping riboswitches, thereby enabling small-molecule-controlled transgene expression without exogenous protein factors. ASP7967 hemifumarate can be used for the study of synthetic RNA switches, gene expression regulation and AAV-based gene therapy-related expression control[1].

IC50 & Target

AC17-4 aptamer

12 nM (Kd)

In Vitro

ASP7967 hemifumarate binds the RNA aptamer AC17-4 with a Kd of 12 nM[1].
ASP7967 (5 μM; 2 days after transfection) hemifumarate activates EGFP expression by approximately 10-fold in HEK293 cells expressing the a8-AC17-4-CPP aptazyme riboswitch[1].
ASP7967 (10 μM; 2 days after transfection) hemifumarate mostly saturates the a8-AC17-4-CPP riboswitch response in HEK293 cells, with an EC50 of approximately 2.3 μM and a fully induced ON level of approximately 50% of the empty-vector control[1].
ASP7967 (0-10 μM; 18 h) hemifumarate does not significantly reduce HEK293 cell viability in the MTT assay[1].
ASP7967 (0.1-10 μM; 2 days after transfection) hemifumarate regulates hEPO secretion from HEK293 cells transfected with pAAV-CMV-hEPO-a8c-AC17-4-CPP, at 10 μM, it upregulates hEPO secretion by approximately 10-fold, reaching 29% of the no-riboswitch control construct[1].
ASP7967 hemifumarate triggers EGFP expression via riboswitches with ON/OFF ratios of 114, 58 and 177 respectively in HEK293 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA Assay[1]

Cell Line: HEK293
Concentration: 10 μM
Incubation Time: 2 days after transfection
Result: Upregulated hEPO secretion by approximately 10-fold in cells transfected with pAAV-CMV-hEPO-a8c-AC17-4-CPP.
Increased hEPO secretion to 29% of the no-riboswitch control construct.

Cell Viability Assay[1]

Cell Line: HEK293
Concentration: 0, 2, 5, 10 µM
Incubation Time: 2 days after transfection
Result: Did not significantly reduce HEK293 cell viability in the MTT assay.
Parmacokinetics
Species Dose Route Tmax
Mice[1] 100 mg/kg p.o. 1 h
In Vivo

ASP7967 (100 mg/kg; p.o.; single administration, 2 weeks after AAV injection; blood collected at 2,4,6,8,24 h postdose) hemifumarate upregulates serum hEPO in BALB/c mice injected with 3 × 1010 GC AAV8-CMV-hEPO-a8c-AC17-4-CPP; serum hEPO peaks at ~115 mIU/mL (6-8 h) with a 7.2-fold elevation vs vehicle, while no hEPO change occurs in mice receiving control AAV8-CMV-hEPO[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 7-week-old male BALB/c mice intravenously injected with 3 × 1010 genome copies of AAV8-CMV-hEPO-a8c-AC17-4-CPP per mouse[1]
Dosage: 100 mg/kg
Administration: Oral administration (p.o.); single administration; 2 weeks after AAV injection
Result: Upregulated serum hEPO expression in mice.
Increased serum hEPO to approximately 115 mIU/mL at 6-8 h postdosing.
Produced a 7.2-fold increase in serum hEPO over vehicle control.
Serum hEPO subsequently decreased in accordance with the decline of ASP7967 concentration in the liver.
Molecular Weight

464.43

Formula

C24H20F2N8O4

CAS No.
SMILES

OC(/C=C/C(O)=O)=O.FC(C=C1)=CC=C1NC2=NC(NC3=CC=C(C=C3)F)=NC(NCC4=NC=CC=N4)=N2.[1/2]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
ASP7967 hemifumarate
Cat. No.:
HY-49538C
Quantity:
MCE Japan Authorized Agent: